Azra AI

Based in the US, Azra AI specializes in artificial intelligence software that enhances oncology care through advanced patient management and identification solutions. Azra AI, founded in 2022, is located in Franklin, US, and focuses on providing an AI platform for oncology care. The company has made one notable deal to date, with its most recent funding round occurring on January 31, 2026. The founder’s history is not available, nor are there any details on subsidiaries or parent companies.

Azra AI offers a comprehensive platform aimed at streamlining oncology care, utilizing AI to improve patient identification and management throughout treatment. The primary product is an AI-powered system that automates the identification of patients needing care by analyzing pathology and radiology reports in real-time. Developed in collaboration with HCA, the platform caters to hospitals and cancer centers across the United States, enhancing patient experience and promoting health equity. Key features include SmartPath Cancer Registry Automation to eliminate manual data entry and a Patient Journey module that tracks patients from suspicion through survivorship.

Azra AI's solutions are designed for adaptability, integrating seamlessly with existing electronic health record (EHR) systems. Azra AI generates revenue through a subscription-based model aimed at healthcare organizations such as hospitals and cancer treatment centers. Clients subscribe to the AI platform, gaining access to features like real-time patient identification and care coordination. Revenue is derived from B2B transactions, with healthcare providers purchasing licenses tailored to their operational needs.

Each client’s pricing plan reflects the customized nature of the services offered, supporting tangible improvements in efficiency and patient revenue. In January 2026, Azra AI raised an undisclosed amount of venture funding from new investor SJF Ventures, which will be utilized to enhance workflows that assist health systems in identifying and supporting cancer patients through artificial intelligence. The company plans to expand its market presence but specific geographic regions for this expansion have not been disclosed. Upcoming product launches and further details on their timeline will be determined as they grow.